{"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"BG000","title":"CDX-3379 and Cetuximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"79","value":"62"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Pharynx/Oropharynx"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Oral Cavity"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Larynx"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Site of Primary Tumor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"17","value":"2.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Duration of Metastatic Disease","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"ECOG 0"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"ECOG 1"}]}],"description":"ECOG Performance Status as published in Am. J. Clin. Oncol (Oken, et al. 1982) 0 = Fully active, able to carry on all pre-disease performance without restriction.\n\n1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}]}